This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barault, L. Articles by Piard, F. Search for Related Content PubMed PubMed Citation Articles by Barault, L. Articles by Piard, F.

Hypermethylator Phenotype in Sporadic Colon Cancer: Study on a Population-Based Series of 582 Cases

¹ Institut National de la Sante et de la Recherche Medicale, U866, Dijon, Université de Bourgogne, ² Service d'Anatomie Pathologique, ³ Registre Bourguignon des Cancers Digestifs, CHRU Dijon, ⁴ Centre de Pathologie, and ⁵ Service de chirurgie digestive, ⁶ Service de Gastroentérologie, CHU Dijon, Dijon, France; and ⁷ Institut National de la Sante et de la Recherche Medicale, U775, Université Paris Descartes; Hôpital Européen George Pompidou, assistance publique, Hôpitaux de Paris, Paris, France

Requests for reprints: Françoise Piard, Service d'anatomie pathologique, CHU Dijon, Faculté de médecine, 7 Boulevard Jeanne d'Arc, 21079 Dijon Cedex, France. Phone: 33-0-3-80-39-33-47; Fax: 33-0-33-80-39-33-50; E-mail: francoise.piard{at}u-bourgogne.fr.

Key Words: CIMP • prognostic • BRAF • KRAS • colonic neoplasm

The CpG island methylator phenotype (CIMP) is a distinct phenotype in colorectal cancer, associated with specific clinical, pathologic, and molecular features. However, most of the studies stratified methylation according to two subgroups (CIMP-High versus No-CIMP/CIMP-Low). In our study, we defined three different subgroups of methylation (No-CIMP, CIMP-Low, and CIMP-High) and evaluated the prognostic significance of methylation status on a population-based series of sporadic colon cancers. A total of 582 colon adenocarcinomas were evaluated using methylation-specific PCR for 5 markers (hMLH1, P16, MINT1, MINT2, and MINT31). No-CIMP status was defined as no methylated locus, CIMP-Low status as one to three methylated loci, and CIMP-High status as four or five methylated loci. Clinicopathologic and molecular characteristics were correlated to the methylation status. Crude and relative survival was compared according to methylation status. In the microsatellite-stable (MSS) group, CIMP-High was significantly associated with proximal location (P = 0.011) and BRAF mutation (P < 0.001). KRAS mutations were more associated with CIMP-High and CIMP-Low status (P = 0.008). A shorter 5-year survival was observed in MSS cancer patients with CIMP-Low or CIMP-High status. These results remained significant in multivariate analysis adjusted for age, stage, and BRAF and KRAS mutational status [CIMP-Low: hazard ratio (HR), 1.85; 95% confidence interval (95% CI), 1.37–2.51; CIMP-High, HR, 2.90; 95% CI, 1.53–5.49 compared with No-CIMP]. Within the high-level microsatellite instability group, no difference in survival was observed between the different CIMP groups. Our results show the interest of defining three subgroups of patients according to their methylation status (No-CIMP/CIMP-Low/CIMP-High). Methylation is an independent prognostic factor in MSS colon cancer. [Cancer Res 2008;68(20):8541–6]

This article has been cited by other articles:

				C. Ausch, V. Buxhofer-Ausch, C. Oberkanins, B. Holzer, M. Minai-Pour, S. Jahn, N. Dandachi, R. Zeillinger, and G. Kriegshauser Sensitive Detection of KRAS Mutations in Archived Formalin-Fixed Paraffin-Embedded Tissue Using Mutant-Enriched PCR and Reverse-Hybridization J. Mol. Diagn., November 1, 2009; 11(6): 508 - 513. [Abstract] [Full Text] [PDF]

				H. S. CROSS, T. NITTKE, and M. PETERLIK Modulation of Vitamin D Synthesis and Catabolism in Colorectal Mucosa: A New Target for Cancer Prevention Anticancer Res, September 1, 2009; 29(9): 3705 - 3712. [Abstract] [Full Text] [PDF]

				K. Nosho, K. Shima, N. Irahara, S. Kure, Y. Baba, G. J. Kirkner, L. Chen, S. Gokhale, A. Hazra, D. Spiegelman, et al. DNMT3B Expression Might Contribute to CpG Island Methylator Phenotype in Colorectal Cancer Clin. Cancer Res., June 1, 2009; 15(11): 3663 - 3671. [Abstract] [Full Text] [PDF]